Developer docs
API playgroundTry for free, no card

Search company profiles

Pearsanta

Full company profile

uuid000hxqa

Namestring
Pearsanta
Legal namestring
Pearsanta, Inc.
Websiteurl
pearsanta.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Pearsanta, Inc. is a Richmond, Virginia-based medical diagnostics company operating as a wholly-owned subsidiary of Aditxt, a publicly-traded biotechnology company. Founded in 2023 and incorporated in Delaware, Pearsanta delivers personalized diagnostic and monitoring solutions under its "Health by the Numbers" positioning, targeting both healthcare providers and individual patients. The company operates a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information, providing a regulated infrastructure footprint for commercial laboratory-developed testing.

The company's core asset is the Mitomic™ testing platform, acquired from MDNA Life Sciences on January 8, 2024. Mitomic™ uses patented mitochondrial DNA (mtDNA)-based methodology for early disease and cancer detection, with current diagnostic tests covering endometriosis and prostate cancer. The technology is described as patent-protected, and the company emphasizes specificity advantages and multidimensional personalization relative to conventional one-size-fits-all diagnostics. No AI/ML capability is referenced; the differentiator is biomarker chemistry and assay architecture rather than algorithmic interpretation.

Pearsanta runs a sales-led, hybrid go-to-market: B2B sales through healthcare provider networks (hospitals, clinics, medical practices) and B2C direct-to-patient testing. Revenue is generated through diagnostic testing services, with the revenue stream described as subscription/recurring in source material. Pricing is not publicly disclosed. Marketing presence is anchored on the corporate website (pearsanta.com) with phone and email as bottom-of-funnel contact channels. The company has no disclosed standalone funding rounds, no public customer logos, and no named management team; commercial scale signals (revenue, test volume, headcount over time) are not provided.

Short descriptiontext

Pearsanta is a Richmond, Virginia-based medical diagnostics subsidiary of Aditxt that delivers personalized diagnostic testing using its proprietary Mitomic™ mitochondrial DNA platform for early disease and cancer detection, targeting healthcare providers and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRichmond, United States
HQ citystring
Richmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, mitochondrial DNA testing, cancer screening, early disease detection, diagnostic laboratory services
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeSubscription Recurring
Description

Pearsanta generates revenue through providing diagnostic testing services focused on early disease and cancer detection using their proprietary mitochondrial DNA technology platform.

pearsanta.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Pearsanta delivers personalized, data-driven diagnostic and monitoring solutions through its proprietary Mitomic™ testing platform, which uses mitochondrial DNA (mtDNA) for early disease and cancer detection. The portfolio includes specific diagnostic tests for endometriosis and prostate cancer, supported by a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information to healthcare providers and patients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pearsanta™ operates as a medical diagnostic and innovation company delivering personalized, data-driven diagnostic and monitoring solutions through its 'Health by the Numbers' approach. The company's product portfolio centers on the acquired Mitomic™ testing platform, which provides early disease and cancer detection using mitochondrial DNA. This core technology platform is complemented by specific diagnostic tests for endometriosis and prostate cancer. The company leverages its CLIA-certified, CAP-accredited monitoring center to handle biosample collection, processing, and delivery of actionable health information, with the goal of enabling providers and patients to detect and monitor health conditions through precise, personalized diagnostics.

Product and service4 records
1Mitomic™ Testing Platform
CategoryMolecular diagnostics platform
Description

A proprietary diagnostic testing platform specializing in early disease and cancer detection using mitochondrial DNA, providing the core technology backbone for Pearsanta's personalized diagnostic and monitoring solutions for healthcare providers and patients.

2Endometriosis Diagnostic Test
CategoryDiagnostic test
Description

A diagnostic test for endometriosis included as part of the Mitomic™ testing platform, designed for early detection of the condition in patients using mitochondrial DNA markers.

3Prostate Cancer Diagnostic Test
CategoryDiagnostic test
Description

A diagnostic test for prostate cancer included as part of the Mitomic™ testing platform, utilizing mitochondrial DNA for early cancer detection in patients.

4CLIA-certified, CAP-accredited Monitoring Center
CategoryDiagnostic laboratory services infrastructure
Description

Pearsanta's operational infrastructure featuring a CLIA-certified and CAP-accredited monitoring center for processing diagnostic tests and delivering actionable health information to providers and patients.

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-08
Description

Pearsanta acquired MDNA Life Sciences' proprietary Mitomic™ testing platform in January 2024. This acquisition provides Pearsanta with mitochondrial DNA-based diagnostic technology for early disease and cancer detection, including tests for endometriosis and prostate cancer.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The originator of the Mitomic™ mitochondrial DNA testing platform that Pearsanta acquired in January 2024. Most directly comparable as a peer in mtDNA-based diagnostics for cancer and other diseases.

TypeDirect peer
Description

Molecular diagnostics company with established women's health (including endometriosis-related work) and oncology tests. Competes for the same provider channel and similar clinical use cases as Pearsanta.

TypeDirect peer
Description

Liquid biopsy and molecular diagnostics leader focused on oncology. Competes directly in the early cancer detection space Pearsanta addresses with its Mitomic™ prostate cancer test.

TypeBroad incumbent
Description

Established cancer screening and diagnostics company with Cologuard and Oncotype products. Operates in the same early-detection, oncology diagnostic market Pearsanta targets.

TypeBroad incumbent
Description

Diversified molecular diagnostics company with established women's health and oncology franchises. Competes broadly in personalized genetic/molecular testing for cancer risk and prognosis.

TypeBroad incumbent
Description

Oncology-focused clinical laboratory and molecular diagnostics provider serving hospitals and oncologists. Directly comparable B2B oncology channel and CLIA/CAP lab operations.

7Tempus AI
TypeBroad incumbent
Description

AI-enabled precision medicine and molecular profiling company focused on oncology. Competes in data-driven, personalized diagnostics for oncology providers and patients.

TypeDirect peer
Description

Molecular diagnostics company focused on minimal residual disease and cancer detection. Directly comparable as a smaller, molecular-diagnostics-only commercial-stage peer.

9Mainz Biomed
TypeEmerging player
Description

Earlier-stage molecular diagnostics company developing molecular cancer screening tests. Comparable to Pearsanta in size, stage, and focus on early cancer detection via proprietary molecular assays.

TypeBroad incumbent
Description

Life science tools and diagnostics company whose diagnostics segment competes in molecular and protein-based specialty diagnostics. Adjacent peer given Pearsanta's molecular testing focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pearsanta

Molecular Diagnosticspearsanta.com

Pearsanta is a Richmond, Virginia-based medical diagnostics subsidiary of Aditxt that delivers personalized diagnostic testing using its proprietary Mitomic™ mitochondrial DNA platform for early disease and cancer detection, targeting healthcare providers and patients.

What Pearsanta does

Pearsanta, Inc. is a Richmond, Virginia-based medical diagnostics company operating as a wholly-owned subsidiary of Aditxt, a publicly-traded biotechnology company. Founded in 2023 and incorporated in Delaware, Pearsanta delivers personalized diagnostic and monitoring solutions under its "Health by the Numbers" positioning, targeting both healthcare providers and individual patients. The company operates a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information, providing a regulated infrastructure footprint for commercial laboratory-developed testing.

The company's core asset is the Mitomic™ testing platform, acquired from MDNA Life Sciences on January 8, 2024. Mitomic™ uses patented mitochondrial DNA (mtDNA)-based methodology for early disease and cancer detection, with current diagnostic tests covering endometriosis and prostate cancer. The technology is described as patent-protected, and the company emphasizes specificity advantages and multidimensional personalization relative to conventional one-size-fits-all diagnostics. No AI/ML capability is referenced; the differentiator is biomarker chemistry and assay architecture rather than algorithmic interpretation.

Pearsanta runs a sales-led, hybrid go-to-market: B2B sales through healthcare provider networks (hospitals, clinics, medical practices) and B2C direct-to-patient testing. Revenue is generated through diagnostic testing services, with the revenue stream described as subscription/recurring in source material. Pricing is not publicly disclosed. Marketing presence is anchored on the corporate website (pearsanta.com) with phone and email as bottom-of-funnel contact channels. The company has no disclosed standalone funding rounds, no public customer logos, and no named management team; commercial scale signals (revenue, test volume, headcount over time) are not provided.

Pearsanta firmographics

Firmographics
Name
Pearsanta
Legal name
Pearsanta, Inc.
Website
https://pearsanta.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Pearsanta is a Richmond, Virginia-based medical diagnostics subsidiary of Aditxt that delivers personalized diagnostic testing using its proprietary Mitomic™ mitochondrial DNA platform for early disease and cancer detection, targeting healthcare providers and patients.
Ownership category
akta.pro rank

Pearsanta industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Molecular diagnostics
  • Mitochondrial DNA testing
  • Cancer screening
  • Early disease detection
  • Diagnostic laboratory services

Where Pearsanta is headquartered

Location

Headquarters

HQ city
Richmond
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pearsanta business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Diagnostic Testing Services: Pearsanta generates revenue through providing diagnostic testing services focused on early disease and cancer detection using their proprietary mitochondrial DNA technology platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Pearsanta product offering

Product offering

Core offering

Pearsanta delivers personalized, data-driven diagnostic and monitoring solutions through its proprietary Mitomic™ testing platform, which uses mitochondrial DNA (mtDNA) for early disease and cancer detection. The portfolio includes specific diagnostic tests for endometriosis and prostate cancer, supported by a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information to healthcare providers and patients.

Product overview

Pearsanta™ operates as a medical diagnostic and innovation company delivering personalized, data-driven diagnostic and monitoring solutions through its 'Health by the Numbers' approach. The company's product portfolio centers on the acquired Mitomic™ testing platform, which provides early disease and cancer detection using mitochondrial DNA. This core technology platform is complemented by specific diagnostic tests for endometriosis and prostate cancer. The company leverages its CLIA-certified, CAP-accredited monitoring center to handle biosample collection, processing, and delivery of actionable health information, with the goal of enabling providers and patients to detect and monitor health conditions through precise, personalized diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mitomic™ Testing Platform A proprietary diagnostic testing platform specializing in early disease and cancer detection using mitochondrial DNA, providing the core technology backbone for Pearsanta's personalized diagnostic and monitoring solutions for healthcare providers and patients.
  • Endometriosis Diagnostic Test A diagnostic test for endometriosis included as part of the Mitomic™ testing platform, designed for early detection of the condition in patients using mitochondrial DNA markers.
  • Prostate Cancer Diagnostic Test A diagnostic test for prostate cancer included as part of the Mitomic™ testing platform, utilizing mitochondrial DNA for early cancer detection in patients.
  • CLIA-certified, CAP-accredited Monitoring Center Pearsanta's operational infrastructure featuring a CLIA-certified and CAP-accredited monitoring center for processing diagnostic tests and delivering actionable health information to providers and patients.

Companies that use Pearsanta

Customer profile

Segments1 record

Ideal customer profiles2 records

Pearsanta technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pearsanta partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MDNA Life SciencescoreTechnology or Integration · 8 January 2024Pearsanta acquired MDNA Life Sciences' proprietary Mitomic™ testing platform in January 2024. This acquisition provides Pearsanta with mitochondrial DNA-based diagnostic technology for early disease and cancer detection, including tests for endometriosis and prostate cancer.

Recent moves4 records

Expansion highlights2 records

Pearsanta competitors and assessment

Company assessment

Direct peers

  • MDNA Life Sciences: The originator of the Mitomic™ mitochondrial DNA testing platform that Pearsanta acquired in January 2024. Most directly comparable as a peer in mtDNA-based diagnostics for cancer and other diseases.
  • Natera: Molecular diagnostics company with established women's health (including endometriosis-related work) and oncology tests. Competes for the same provider channel and similar clinical use cases as Pearsanta.
  • Guardant Health: Liquid biopsy and molecular diagnostics leader focused on oncology. Competes directly in the early cancer detection space Pearsanta addresses with its Mitomic™ prostate cancer test.
  • Personalis: Molecular diagnostics company focused on minimal residual disease and cancer detection. Directly comparable as a smaller, molecular-diagnostics-only commercial-stage peer.

Broad incumbents

  • Exact Sciences: Established cancer screening and diagnostics company with Cologuard and Oncotype products. Operates in the same early-detection, oncology diagnostic market Pearsanta targets.
  • Myriad Genetics: Diversified molecular diagnostics company with established women's health and oncology franchises. Competes broadly in personalized genetic/molecular testing for cancer risk and prognosis.
  • NeoGenomics: Oncology-focused clinical laboratory and molecular diagnostics provider serving hospitals and oncologists. Directly comparable B2B oncology channel and CLIA/CAP lab operations.
  • Tempus AI: AI-enabled precision medicine and molecular profiling company focused on oncology. Competes in data-driven, personalized diagnostics for oncology providers and patients.
  • Bio-Techne: Life science tools and diagnostics company whose diagnostics segment competes in molecular and protein-based specialty diagnostics. Adjacent peer given Pearsanta's molecular testing focus.

Emerging players

  • Mainz Biomed: Earlier-stage molecular diagnostics company developing molecular cancer screening tests. Comparable to Pearsanta in size, stage, and focus on early cancer detection via proprietary molecular assays.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Pearsanta social profiles

Digital presence

Pearsanta compliance and trust

Trust signal

Compliance2 records

Pearsanta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pearsanta leadership team

Management profile

Number of profiles

Pearsanta funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pearsanta M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pearsanta

What does Pearsanta do?

Pearsanta delivers personalized, data-driven diagnostic and monitoring solutions through its proprietary Mitomic™ testing platform, which uses mitochondrial DNA (mtDNA) for early disease and cancer detection. The portfolio includes specific diagnostic tests for endometriosis and prostate cancer, supported by a CLIA-certified, CAP-accredited monitoring center that handles biosample collection, processing, and delivery of actionable health information to healthcare providers and patients.

Is Pearsanta a public or private company?

Pearsanta is a private company. It is classified as corporate owned and is currently operating.

When was Pearsanta founded?

Pearsanta was founded in 2023. It employs 1 to 10 people.

Where is Pearsanta based?

Pearsanta is headquartered in Richmond, United States, in the North America region.

How does Pearsanta make money?

One revenue line is on record: diagnostic Testing Services.

Who are Pearsanta's main competitors?

Direct peers on record are MDNA Life Sciences, Natera, Guardant Health and Personalis. Broad incumbents are Exact Sciences, Myriad Genetics, NeoGenomics, Tempus AI and Bio-Techne. Mainz Biomed is listed as an emerging player.

Does Pearsanta have an API?

No public API is recorded for Pearsanta.

What industry is Pearsanta in?

Pearsanta's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology fPearsanta, a subsidiary of Aditxt, engaged Spartan Capital Securities as lead underwriter for its planned IPO. The offering aims to support clinical validation and commercial rollout of its Mitomic mitochondrial DNA-based cancer detection tests. The IPO is part of Aditxt's Acquire, Build, Capitalize strategy.Business Wire BlogAditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern TimeAditxt will host a virtual fireside chat on February 21, 2025, with CEO Amro Albanna to update on corporate developments, including subsidiary status and pipeline advancements. The session will cover Adimune's autoimmunity treatments and Pearsanta's early cancer detection program, with a planned IPO for 2025. Questions can be submitted by February 20th.InvezzBioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary PresidentAditxt appointed Christopher Mitton as president of its majority-owned subsidiary Pearsanta Inc., which focuses on precision health. Mitton will continue as CEO of MDNA Life Sciences and brings over two decades of medical diagnostics leadership. The company expects his expertise to drive Pearsanta's commercial success.HomepagePearsanta Acquires MDNA’s Mitomic Platform for Endometriosis and Ovarian Cancer Detection for $25MPearsanta, a subsidiary of Aditxt, has acquired the Mitomic testing platform from MDNA Life Sciences for approximately $25 million to expand its capabilities in early disease and cancer detection. The acquisition includes the Mitomic Endometriosis Test (MET) and other assets targeting conditions such as ovarian, prostate, lung, and breast cancer using mitochondrial DNA biomarkers. This strategic move aims to provide less invasive diagnostic options and enhance Pearsanta's portfolio in women’s health and oncology.Business Wire BlogAditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at ApproximatelAditxt's subsidiary Pearsanta acquired MDNA Life Sciences' Mitomic platform for early disease and cancer detection. Consideration includes 50,000 Aditxt shares, warrants, $25 million preferred stock, and up to $3.2 million in transition payments. The deal aims to expand Pearsanta's diagnostic offerings in 2024 and beyond.Business Wire BlogAditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at ApproximatelAditxt, Inc. announced that its subsidiary, Pearsanta, Inc., has acquired MDNA Life Sciences Inc.’s proprietary Mitomic™ testing platform for early disease and cancer detection. The transaction involves $25 million in preferred stock, warrants, and potential transition service payments, expanding Pearsanta's portfolio with non-invasive diagnostic tests for conditions such as endometriosis and prostate cancer.Business Wire BlogAditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and NaPearsanta, a wholly-owned Aditxt subsidiary, signed a non-binding LOI to acquire Natural State Laboratories and Natural State Genomics. The deal, subject to due diligence, includes cash, debt assumption, and an earnout not exceeding $55 million, with J. Ahmad Brown to become CEO. The acquisition aims to expand testing capacity and payor access.BioSpaceAditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.Aditxt retained Riverside Management Group to advise on strategic M&A for its subsidiary Pearsanta and other programs. Pearsanta, focused on commercializing AditxtScore, aims to achieve financial milestones in 2023. The company expects to share highlights with shareholders.